
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc. is projected to experience significant revenue growth primarily driven by its Signatera molecular residual disease testing, which has shown a remarkable 54% year-over-year increase in volumes. The company has reported an impressive revenue beat of approximately $80 million in the third quarter and has revised its 2025 revenue guidance upwards by $160 million, reflecting strong operational performance. Furthermore, Natera's initiatives to expand reimbursement coverage in additional cancer types are expected to enhance average selling prices and improve gross margins, thereby bolstering operating cash flow.
Bears say
Natera Inc faces a negative outlook primarily due to eroding margins caused by reductions in in-network pricing and the potential inclusion of average risk patients, which could further compress average selling prices for its Panorama product. Regulatory setbacks or unfavorable reimbursement scenarios may delay the company's expansion efforts and adversely impact product adoption, leading to heightened risks for its financial performance. Consequently, without strong data or successful navigation of these challenges, Natera's future growth potential appears limited, which could negatively affect its market position and investor sentiment.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares